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Circulating stem cells of different origin have been
demonstrated to improve repair of various organs
both after systemic and local application, although
the mechanisms that cause these effects are still
not fully understood. We have used a combination
of DNA microarray analysis and in vitro migration as-
says to screen for molecules that mediate homing of
long-term renewing adult bone marrow-derived mul-
tipotent mesenchymal stem cells (BM-MASCs). We
show that the cytokine receptor CCR2 is necessary
for organ-specific homing of bone marrow-derived
MASCs to the heart in a transgenic mouse model
and into hearts damaged by ischemia/reperfusion.
Homing and migration of stem cells was dependent
on the intracellular adaptormolecule FROUNT,which
interacts with CCR2. FROUNT was required for po-
larization of MASCs, resulting in clustering of CCR2
and reorganization of the cytoskeleton. Recruited
MASCs summoned by the CCR2 ligand MCP-1/
CCL2 expressed SDF1, which might trap additional
bone marrow-derived circulating cells to contribute
to the complex process of homing and retention
of circulating stem and progenitor cells to remodel
diseased organs.
INTRODUCTION
Cell therapy currently attracts growing interest as a new
approach to treat diseases of the heart, including heart failure.
Several different types of stem/progenitor cells have been
used in various preclinical and clinical trials. In particular, bone
marrow-derived multipotent adult mesenchymal stem cells
(BM-MASCs), mesenchymal stem cells (MSCs), and endothelial
precursor cells (EPCs), which possess a certain degree of multi-
potency, have attracted attention as therapeutic tools since they
can be obtained with relative ease and expanded in culture
(Dimmeler et al., 2005). So far, most studies both in animals
and in humans reported encouraging results in respect to post
myocardial infarction remodeling and ventricular performance.
Results from initial nonrandomized clinical trials, which were
primarily designed for safety rather than efficacy, demonstrated566 Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc.a moderate improvement of heart function after stem cell
therapy, although most of the beneficial effects were lost during
the follow-up period (Wollert et al., 2004). More recent random-
ized, placebo-controlled clinical studies involving larger groups
of patients suggested small but significant improvements in left
ventricular function, although the underlying mechanisms have
remained enigmatic (see Povsic and Peterson, 2006 for a recent
review).
There is no doubt that homing and tissue integration are
prerequisites for a functional benefit of stem/progenitor cell ther-
apies irrespective of the type of cells used and their quality. Any
improvement of existing cell-based therapeutic approaches will
depend on a better understanding of the interaction of stem cells
with the environment that leads to homing and tissue integration.
The molecular mechanisms that direct mobilization and homing
of bone marrow-derived cells such as MSC, MASC, and EPCs
are only partially understood. One of the best-studied examples
is the vascular endothelial growth factor and stromal-derived
factor-1 loop (VEGF-SDF1 loop), leading to VEGF-dependent
mobilization of hematopoietic cells to the blood, which are
then ‘‘trapped’’ in the close proximity to angiogenic vessels by
SDF1, that seems mainly expressed by perivascular myofibro-
blasts (Grunewald et al., 2006). Although the identity of circulat-
ing cells, which are recruited by the interplay of VEGF and SDF1,
has not been fully determined, it is likely that EPCs contribute to
this process via the SDF1 receptor CXCR4 since neutralizing
antibodies against CXCR4 profoundly inhibited EPC-induced
angiogenesis as well as VEGF- and SDF-1-induced migration
(Walter et al., 2005). Likewise, it has been reported that a subset
of mesenchymal stem cells strongly express functionally active
CXCR4, which promoted migration to bone marrow (Sordi
et al., 2005). Another factor, which has been implicated in the
homing of MSCs, is MCP-3, which is transiently upregulated in
the infarcted heart after experimental ligation of the coronary
artery together with MCP-1/CCL2, MIP-1a, and MIP1b (Schenk
et al., 2007). MCP-3 interacts with CCR1, CCR2, and CCR3,
while MCP-1/CCL2 signals via CCR2 (Daugherty et al., 1996).
CCR2 is a G protein-coupled receptor that is activated by
MCP-1/CCL2, CCL7, CCL8, CCL12, and CCL13. Activation of
intracellular effectors of CCR2 such as adenylate cyclases,
PLCßs, PI3Ks, MAPKs, and RhoGEFs occurs mostly via hetero-
trimeric G-proteins of the GI/O and the Gq family (Wong and Fish,
2003). In addition, Terashima et al. demonstrated that activated
CCR2 interacts directly with FROUNT, a unique clathrin heavy-
chain repeat homology protein, which forms clusters at the cell
front during chemotaxis. Overexpression of FROUNT enhances
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linking activated CCR2 to the PI(3)K-Rac-lamellipodium protru-
sion cascade (Terashima et al., 2005).
We have recently described the isolation of multipotent adult
mesenchymal stem cells (MASC) from different organs of mice
including the bone marrow. MASCs can be induced to express
cell-type specific markers that are characteristic for heart, mus-
cle, brain, and liver cells (Belema-Bedada et al., 2005). After
injection into mouse blastocysts, these cells contributed to the
development of chimeric embryos in vivo, although functional
differentiation into skeletal myotubes occurred via IL-4-depen-
dent fusion with native myotubes and not by cell autonomous
differentiation (Schulze et al., 2005).
Here we show that MASCs rely on the cytokine receptor CCR2
for organ-specific homing. CCR2-mediated activation of stem
cells critically depended on the intracellular adaptor molecule
FROUNT, which caused polarization of stem cells, resulting in
clustering of CCR2 and reorganization of the cytoskeleton.
RESULTS
mBM-MASCs Are Long-Term Self-Renewing Cells
that Home to the Bone Marrow of Wild-Type Mice
We have previously devised a protocol for the isolation of multi-
potent mesenchymal cell populations (mBM-MASCs) from adult
murine bone marrow, which show a remarkable developmental
plasticity as indicated by the expression of various cell-type spe-
cific differentiation markers upon induction (Belema-Bedada
et al., 2005). Our protocol (Belema-Bedada and Braun, 2008;
Belema-Bedada et al., 2005) allows rapid isolation of primary
MASCs (mBM-MASCs1 [CD34/Sca-1high] or mBM-MASCs2
[CD34+/ Sca-1moderate] hereafter referred to as MASC-1 and
MASC-2), which can be propagated for several passages in vitro
(>25 passages) without signs of senescence and cellular trans-
formation (i.e., contact inhibition, lack of tumor formation after
transplantation into immune-deficient mice). MASCs also partic-
ipate in embryonic development of chimeric mice after blastocyt
injection without causing obvious malformations, although the
degree of chimerism is limited (Schulze et al., 2005). The majority
of metaphase spreads of MASCs (12 out of 15 for MASC-1; 9 out
of 15 for MASC-2) were euploid and lacked chromosomal aber-
rations, including translocations as indicated by multicolor FISH
analysis (Figure S1 available online). Similar results have been
obtained recently for mouse and human MSCs (Bochkov et al.,
2007; Tolar et al., 2007), which show a certain degree of cytoge-
netic abnormalities even at low passage numbers, a phenome-
non that is also well known for primary ES cultures (Nichols
et al., 1990). It has to be mentioned that the incidental occur-
rence of aneuploid metaphase spreads might also be caused
by preparation artifacts and does not necessarily indicate insta-
bility of the karyotype.
The expression of various stemness markers in these cells and
the ability for self-renewal in vitro prompted the question whether
mBM-MASCs competitively repopulate their niche within the
bone marrow stroma for an extended time in vivo. A group of
3-month-old ICR mice (n = 5) was injected via the tail vein with
2.5 to 3 3 105 of mBM-MASCs1 or mBM-MASCs2 cells sus-
pended in 75 ml PBS and analyzed after 3 months (n = 3) and 6
months (n = 2). In each case, EGFP-positive cells were recoveredfrom the bone marrow showing a similar morphology and similar
proliferation properties as parental cells (Figure 1A). Essentially
the same results were obtained for mBM-MASCs1 and mBM-
MASCs2. In the course of this study, we collectively refer to
both cell populations as mBM-MASCs unless differences be-
tween both populations were noted. To further prove the origin
of EGFP-positive cells, we confirmed the expression of EGFP
in isolated cells by RT-PCR (Figure 1B). The number of EGFP-
positive cells within the bone marrow, which were derived from
injected cells, was relatively low in the competitive stromal
environment. Immunostaining for EGFP expression of cells
isolated from the bone marrow and FACS analysis of EGFP au-
tofluorescence revealed that <1% of lin bone marrow cells
originated from injected cells both 3 and 6 months after trans-
plantation (Figure 1A and data not shown). No EGFP-expressing
cells were identified in CD45+ cells, suggesting that mBM-
MASCs have a limited, if any, hematopoietic potential (data not
shown).
Serial transplantation from donors to primary and secondary
recipients has been widely used in the study of hematopoietic
stem cells to analyze long-term self-renewal abilities and to
investigate possible changes in the developmental potential of
stem cells (Weissman, 2000). To investigate whether mBM-
MASCs, which had been maintained for several months in a re-
cipient host and exposed to two rounds of isolation and cultiva-
tion, were still able to populate the bone marrow of recipient
mice, EGFP-positive cells were transplanted into a secondary
host. mBM-MASCs were readily isolated from the bone marrow
of secondary host with roughly the same efficiency as from the
primary recipient (Figure 1). Isolated cells also maintained their
ability to respond to inductive cues by expression of cell type-
specific markers (data not shown) (Belema-Bedada et al.,
2005). Interestingly, we were unable to locate EGFP-positive
cells in other organs of primary and secondary hosts including
liver, heart, skeletal muscle, brain, and spleen 3 months after
transplantation, indicating tissue-specific homing of injected
cells.
Identification of Potential Homing Receptors
of mBM-MASCs
The restricted tissue distribution of EGFP-labeled mBM-MASCs
in recipient mice indicated the presence of a specific homing
mechanism that guided transplanted cells into the bone marrow
after transplantation. Since directed homing and tissue integra-
tion might be the key to an improvement of existing therapeutic
applications of stem cells irrespective of their mode of action,
we wanted to learn more about the molecule that mediated hom-
ing of mBM-MASCs. We therefore decided to investigate the
expression of potential homing receptors in mBM-MASCs by
DNA microarray analysis. Probe sets from all groups were char-
acterized according to gene ontology (GO) annotation (Ash-
burner et al., 2000) to identify cell surface receptors expressed
by mBM-MASCs. Figure S2 depicts a selection of chemokine
receptors and other ligand-activated receptors that have been
implicated in homing and migration. We detected the presence
of the cytokine receptors CCR2 and CCR10 in mBM-MASCs.
CCR2 and CCR10 have both been implicated in homing and
migration of various different cell types, including mesenchymal
stem cells (Spring et al., 2005). Furthermore, mBM-MASCsCell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc. 567
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contribute to cellular migration and homing including c-met and
Fgf receptors (Neuhaus et al., 2003). The expression of CCR2,
CCR10, Tgfbr1, Tgfbr2, Pdgfra, Pdgfrb, Il6st, Fgfr1, and Fgfr2
was further confirmed by RT-PCR analysis (Figure S3).
Immunofluorescence staining revealed that most, but not all,
mBM-MASCs express CCR2 (Figure S4). CCR2 expression
was also found in human mesenchymal stem cells and in
C2C12 myoblasts (Figure S4). mBM-MASCs did also express
high amounts of CXCL12 (SDF-1), which had been implicated
with the trafficking of bone marrow-derived circulating cells
(Grunewald et al., 2006) and moderate amounts of CXCR3,
CXCR4, and CXCR6 (Figure S2 and data not shown).
MCP-1 and HGF/SF Strongly Stimulate Migration
of mBM-MASCs In Vitro
The expression of putative homing receptors does not necessar-
ily prove their ability to guide cells to specific targets. We there-
fore analyzed the ability of several ligands of putative homing
receptors to induce targeted migration of mBM-MASCs in vitro
in a modified Boyden microchemotaxis chamber system (Fig-
ure 2A). Both mBM-MASCs1 and -2 showed random migration
in the absence of ligands, although this activity was relatively
low compared to the addition of chemoattractants (Figure 2B).
Most of the 19 factors had been reported to elicit migration of
Figure 1. mBM-MASCs Are Long-Term Self-Renewing Stem Cells
(A) Serial transplantation of genetically labeled mBM-MASCs by intravenous
administration and isolation from the bone marrow. mBM-MASCs were
expanded clonally, infected with an EGFP-expressing retrovirus, and trans-
planted into recipient immune-compatible mice. Descendants of mBM-
MASCs cells were identified by EGFP-fluorescence in bone marrow isolates
of primary and secondary recipients and expanded for further analysis and
transplantation experiments.
(B) RT-PCR analysis of EGFP expression in primary mBM-MASCs and after
primary and secondary transplantation.568 Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc.various different cell types. Therefore, it was no surprise that
all 19 factors stimulated targeted migration of mBM-MASCs,
at least to a certain degree (Figure 2). The response of mBM-
MASCs to different cytokines followed a bell-shaped concentra-
tion response curve with the exception of Eotaxin and PDGF-AB
(Figure S5 and data not shown). A strong response was caused
by MCP-1 and HGF/SF, which signal via CCR2 or CCR4 and
Figure 2. MCP-1 and HGF Strongly Stimulate Targeted Migration of
mBM-MASCs In Vitro
mBM-MASCs1 (A) and -2 (B) were exposed to different cytokines and growth
factors in a Boyden microchemotaxis chamber assay to identify potential che-
moattractants. Cells, which had migrated toward the source of chemoatrac-
tants (lower chamber) by passing through a membrane filter, were quantified
using the ImageJ software. Concentration of cytokines used was as follows:
PDGF-AA, 20 ng/ml; PDGF-AB, 20 ng/ml; NAP-2, 5ng/ml; MIP-4, 10 ng/ml, Eo-
taxin, 10 ng/ml; M-CSF, 20 ng/ml; TNF-a, 10 ng/ml; TGF-b, 10 ng/ml; MCP-1,
50 ng/ml; MCP-4, 800 ng/ml; MIP-2a, 5 ng/ml; OSM, 40 ng/ml; IL-8, 100 ng/ml;
MIP-3a, 100 ng/ml; Lymphotactin, 100 ng/ml; FGF-acidic, 20 ng/ml; HGF,
30 ng/ml; IGF-1, 100 ng/ml; FGF-basic, 30 ng/ml. Data represent mean ± SD
(n = 4). Representative examples of MCP-1 stimulated migration of mBM-
MASCs1 and -2 after staining with Hoechst33258 (C).
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activity of mBM-MASCs1 and -2 were noted. Both populations,
which differ in the expression of CD34 and Sca1 (MASCs1 are
CD34/Sca-1high; MASCs2 are CD34+/Sca-1moderate) showed
a similar response pattern with only minor differences concern-
ing the reaction to PDGF-AA, PDGF-AB, NAP-2, and FGF-1 (Fig-
ures 2A and 2B). We also detected a strong chemoattractive ac-
tivity of VEGF and SDF1 (Figure S5). The pronounced stimulation
of migration by MCP-1 suggested that the CCR2 receptor, which
we found to be expressed in mBM-MASCs, might be instrumen-
tal for targeted migration and homing of these cells.
Directed Expression of MCP-1 in the Myocardium
of Transgenic Mice Mobilizes mBM-MASCs
and Leads to Specific Homing into the Heart
To probe the physiological relevance of MCP-1-mediated homing
processes in vivo and to address directly the ability of MCP-1 to
guide mBM-MASCs into individual organs, we utilized a trans-
genic model in which MCP-1 is specifically expressed in the myo-
cardium (Kolattukudy et al., 1998). Genetically labeled mBM-
MASCs1 and -2 (3 3 105) were injected intravenously into 12- to
16-week-old MyHC-MCP-1 and control mice (n = 12) (Martire
et al., 2003). Injected animals were sacrificed after 7 and 14
days, and tissue samples were processed for immunofluores-
cence staining using an antibody against EGFP. Engraftment of
EGFP-expressing cells was clearly visible in hearts of MCP-1
transgenic mice (Figures 3Ag–3Ai), but not in wild-type control
mice. Virtually every microscopic field in hearts of transgenic
mice contained numerous EGFP-expressing cells, which either
formed large clusters of cells (Figures 3Ag–3Ai) or were scattered
within the myocardium (Figures 3Ba–3Bd). Occasionally, we also
found EGFP-labeled, mBM-MASCs1- and -2-derived cells in the
liver and in the spleen of MCP-1 transgenic mice, although the
amount of such cells was much lower in these tissues, and
most sections did not contain EGFP-expressing cells (Figures
3Aa–3Af). A quantitative assessment of the number of MASCs
in different organs revealed that hearts of MyHC-MCP-1 mice
contained 20.70 ± 1.7 cells/microscopic field in comparison to
0.9 ± 0.7 in skeletal muscle, 0.8 ± 0.4 in the brain, and 1.6 ±
0.9 in the liver (n = 6) (Figure S6A). In an additional attempt to
quantify homing and engraftment of transplanted mBM-MASCs
in different tissues and to avoid potential staining artifacts, we
performed real-time RT-PCR analysis of whole organs (Figure 4).
Only a low expression of EGFP-RNA was found in skeletal mus-
cle, brain, and kidney reflecting the low number of of mBM-
MASCs-derived cells in these tissues (Figures 3 and 4). In the
heart, a strong expression of EGFP was detected, which was
eight times higher than in the liver or the spleen, indicating that
mBM-MASCs-derived cells predominantly homed and engrafted
into the heart (Figure 4). Clearly, the homing of mBM-MASCs-
derived cells into the heart was dependent on the expression
of MCP-1 since no significant amounts of EGFP mRNA were
detected in the hearts of wild-type control animals (data not
shown).
It has been proposed that VEGF induces expression of SDF-1
in activated perivascular myofibroblasts leading to an entrap-
ment of circulating bone marrow-derived cells in the vicinity of
growing vessels (Grunewald et al., 2006). To analyze the expres-
sion of SDF-1 in vivo by engrafted EGFP-expressing cells,double-labeling with EGFP and SDF-1 antibodies were per-
formed. mBM-MASCs, which had homed into the hearts of
MCP-1 transgenic mice after intravenous administration, were
strongly positive for SDF-1 irrespective of whether these cells
formed clusters of cells (Figures 3Ba–3Bc) or were scattered
within the myocardium (Figures 3Bd–3Bf). We also detected
additional SDF-1-positive cells in the vicinity of engrafted
Figure 3. mBM-MASCs Home Preferentially to the Hearts of
MyHC-MCP-1 Mice
(A) MyHC-MCP-1 mice were intravenously injected with genetically labeled
mBM-MASCs-eGFP cells. Sections were prepared from liver (a–c), spleen
(d–f), and heart (g–i) 14 days later and stained with an antibody against
EGFP. EGFP-labeled cells were occasionally detected in some sections
from liver (a–c) and spleen (d–f), while virtually all sections derived from the
heart (g–i) contained large numbers of mBM-MASCs-eGFP cells.
(B) mBM-MASCs that have engrafted into the heart strongly express SDF-1.
Sections were reacted with antibodies against EGFP (a and d) and SDF-1 (b
and e). Merged images of (a) and (b) and of (d) and (e) are shown in (c) and
(f), respectively.Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc. 569
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sponded to the release of SDF-1 or were recruited by the en-
grafted cell population.
Organ-Specific Homing of mBM-MASCs Depends
on FROUNT, a Clathrin Heavy-Chain Repeat
Homology Protein
The cellular mechanisms that cause homing of stem cells are only
barely understood. To begin to decipher the machinery that
transmits chemotactic homing signals within stem cells and to
prove a decisive function of CCR2-mediated receptor signaling,
we decided to interfere with the function of FROUNT. FROUNT
links activated CCR2 to the PI(3)K-Rac-lamellipodium protrusion
cascade and stimulates chemotaxis of macrophages (Terashima
et al., 2005). Full-length FROUNT or a truncated version, which
contains a preserved CCR2-binding domain that competes
with endogenous FROUNT in CCR2 binding and, thus, serves
as a dominant-negative effector, were cloned together with an
IRES-EGFP cassette into a lentiviral expression vector (Lois
et al., 2002) and were subsequently used to infect mBM-MASCs.
Infected cells were enriched by FACS sorting (EPICS ELITE ESP;
Beckman Coulter) through gating for EGFP-expressing cells re-
sulting in homogenous cell populations (>95% infected). Western
blot analysis revealed that expression of DN-FROUNT in mBM-
MASCs did not alter the expression level of CCR2 (Figure S7).
Figure 4. Dominant-Negative FROUNT Efficiently Abrogates
Organ-Specific Homing of mBM-MASCs
(A) mBM-MASCs were exposed to MCP-1 and HGF in a Boyden mi-
crochemotaxis chamber assay. A strong stimulation was achieved
by MCP-1 and HGF. Preincubation of mBM-MASCs with antibodies
against CCR2 inhibited MCP-1-induced targeted migration, but not
migration stimulated by HGF. Similarly, infection of mBM-MASCs
with a retrovirus expressing DN-FROUNT inhibited MCP-1-induced
targeted migration, but not migration stimulated by HGF. Concentra-
tion of cytokines used was as follows: MCP-1, 50 ng/ml; HGF, 30 ng/ml.
Data represent mean ± SD (n = 5). **p < 0.01. (B) Quantification of hom-
ing of mBM-MASCs and mBM-MASCs expressing dominant-negative
FROUNT (DNF) into different organs of MyHC-MCP-1 mice by real-
time RT-PCR. Values of the quantitative RT-PCR reactions are dis-
played in (C) after normalization to acidic ribosomal phosphoprotein
(m36B4) and are expressed as the ratio of the normalized expression
of EGFP to a reference transcript (GAPDH). Data represent mean ± SD
(n = 3).
Surprisingly, overexpression of active FROUNT led to
a rapid loss of the stem character of mBM-MASCs and
was, therefore, excluded from further analysis (data not
shown).
We first tested the ability of DN-FROUNT to interfere
with MCP-1-mediated targeted migration of mBM-
MASCs in vitro in the modified Boyden chamber assay.
Expression of DN-FROUNT efficiently blocked MCP-1
mediated targeted migration while it had no effect on
the migratory activity caused by HGF, VEGF, SDF1, or
a combination of VEGF and SDF1 (Figure 4A and Fig-
ure S5). To verify that the effect of MCP-1 was mediated
directly via binding to CCR2, we examined the effects of
neutralizing CCR2-antibodies on the migration of mBM-
MASCs. As shown in Figure 4A, MCP-1-stimulated migration
of mBM-MASCs was strongly inhibited by CCR2-antibodies
(20 ng/ml), while no significant inhibition of HGF-stimulated
migration was observed.
Next, we wanted to investigate whether inhibition of FROUNT
also blocks homing of transplanted mBM-MASCs in vivo. DN-
FROUNT-infected cells and cells infected with an EGFP-control vi-
rus were injected into the tail vein of transgenic MCP-1 mice (n = 6
for each cell preparation). Injected animals were sacrificed after 14
days, and tissue samples were processed for immunofluorescence
staining using an antibody against eGFP and for RT-PCR analysis. A
low engraftment of DN-FROUNT-infected cells was found by
EGFP-antibody staining in the heart (0.8 ± 0.6 cells/microscopic
field) and in other organs of MCP-1 transgenic mice (0.4 ± 0.5 in
skeletal muscle, 0.3 ± 0.4 in brain, and 1.5 ± 0.5 in the liver [n = 6])
(Figure S6A), while mBM-MASCs infected with the EGFP-control
virus were present in the hearts of MCP-1 transgenic mice at the
same rate as in the previous experimental series (Figure 3;
Figure S6A). Likewise, we measured a strong expression of
EGFP-mRNA by real-time RT-PCR in the hearts of MCP-1 mice,
which had been infected with the EGFP-control virus, but not in
mice, which received cells infected with the DN-FROUNT-IRES-
EGFP virus (Figure 4B, C). We concluded that blocking of
FROUNT function abolished organ-specific homing of mBM-
MASCs in vivo.570 Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc.
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for Homing of mBM-MASCs to Hearts Damaged
by Ischemia/Reperfusion
We next wanted to know whether mBM-MASCS home to the in-
jured heart in a disease model that does not rely on overexpres-
sion of MCP-1 and whether such a type of homing would also de-
pend on the CCR2-FROUNT axis. We therefore injected 33 105
genetically labeled mBM-MASCs1 and -2 intravenously into 12-
to 16-week-old ICR mice (n = 5) that had been undergone ische-
mia/reperfusion of the myocardium by transient ligation of the
LAD for 90 min. This procedure results in the formation of scar
tissue devoid of cardiomyocytes and formation of a border
zone (BZ) characterized by enhanced deposition of collagen-3.
The remote zone (RZ) is further apart from the infarct area and
is characterized by the normal presence of cardiomyocytes
and no enhanced collagen depositions (Figure S8). Immunofluo-
rescence-based analysis of injected animals 7 days after tran-
sient LAD ligation and injection of cells revealed the presence
of numerous eGFP-labeled MASCs in the BZ (Figures 5A–5C),
while comparatively few labeled cells were detected in the RZ
(Figures 5D–5F). A quantitative assessment of the number of
MASCs showed 28.81 ± 1.75 cells/microscopic field in the BZ
in comparison to 3.6 ± 1.57 cells /microscopic field in the RZ
(n = 5) (Figure S6B). Next, we investigated whether inhibition of
FROUNT blocks homing of transplanted mBM-MASCs to the
damaged myocardium. DN-FROUNT-infected cells were in-
jected into the tail veins of ischemically damaged mice (n = 6).
Injected animals were sacrificed after 7 days and analyzed as
described above (Figures 5J–5L). We found a strong decrease
of engraftment of DN-FROUNT-infected cells in the BZ (2.2 ±
0.75 cells/microscopic field) and also in the RZ (0.33 ±
0.28 cells/microscopic field) (Figure S6B). We concluded that
blocking of FROUNT function strongly inhibited recruitment of
mBM-MASCs to ischemically damaged myocardium.
FROUNT Is Instrumental for Clustering of CCR2
and for Reorganization of the Cytoskeleton in MASCs
To learn more about the processes that control targeted migra-
tion and homing of mBM-MASCs, we analyzed the subcellular
distribution of CCR2 and FROUNT in MCP-1/CLL2 stimulated
cells by immunofluorescence staining and laserscan micros-
copy. In all experiments, mBM-MASCs were used that had either
been infected with an EGFP control virus or a virus expressing
DN-FROUNT-IRES-EGFP. Infected cells were sorted by FACS
to generate homogenous cell populations (>95% infected). In
the absence of MCP-1, CCR2 was mainly confined to the plasma
membrane resulting in a diffuse cellular staining (Figure 6A),
although some cells showed a perinuclear accumulation of
CCR2 (inlet in Figure 6A). FROUNT was either localized within
the cytoplasm or at a perinuclear position in unstimulated
mBM-MASCs (Figure 6B). The latter localization would also con-
cur with the proposed function of FROUNT/Nup85 as a part of
the nuclear pore complex (Cronshaw et al., 2002). Stimulation
of mBM-MASCs by MCP-1 resulted in clustering of CCR2 within
the plasma membrane (Figure 6C). Interestingly, the accumula-
tion of CCR2 occurred always on one side of the nucleus, indi-
cating polarization of the cells, although MCP-1 was not applied
in a vectored manner (Figure 6; Figure S9). The relocalization of
FROUNT followed a similar pattern. Again, the accumulation andclustering of FROUNT usually occurred at one side of the nu-
cleus with only rare exceptions (Figure 6D, inlet; Figure S9). Ex-
pression of a dominant-negative version of FROUNT that carried
only the C-terminal, CCR2-binding domain of FROUNT effi-
ciently inhibited clustering of CCR2 and FROUNT, as well as
the polarization of mBM-MASCs (Figures 6E and 6F). Prevention
of CCR2 activation by dominant-negative FROUNT leads to
predominant cytoplasmic localization of CCR2 (Figure 6E), while
FROUNT was detected in granules and in the cytoplasm
(Figure 6F). Similar staining patterns were observed during
directed migration in a Boyden chamber assay when mBM-
MASCs were induced by MCP-1 to migrate through a filter
with 10 mm pore sizes (data not shown).
Directional sensing and polarization has to be transmitted to
the migratory apparatus of a cell in order to achieve targeted
Figure 5. Efficient Homing of mBM-MASCs to the Border Zone
of Mouse Hearts Damaged by Ischemia/Reperfusion Depends
on Intact CCR2/FRONT Signaling
mBM-MASCs home preferentially to the border zone (BZ) of hearts damaged
by ischemia/reperfusion (A–F). Genetically labeled mBM-MASCs-eGFP were
intravenously injected into mice, which had been subjected to ischemia/reper-
fusion for 90 min. Immunofluorescence staining of sections covering the scar,
the border zone (A–C), and the remote zone (RZ) (D–F) 7 days after ischemia/
reperfusion is shown. Sections were reacted with antibodies against EGFP
and counterstained with DAPI. Only few injected cells were present in the
RZ (D–F) compared to the BZ (A–C). Presence of intravenously injected
eGFP-labeled cells infected with a control retrovirus (G–I) and infected with
a retrovirus expressing DN-FROUNT (J–L) 7 days after ischemia/ reperfusion
in the BZ is shown.Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc. 571
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geted movement of cells goes along with the formation of ac-
tin-filled projections (Devreotes and Janetopoulos, 2003). We
therefore visualized the distribution of F-actin in MCP-1-stimu-
lated cells by phalloidin staining and assessed the formation of
pseudopodia in mBM-MASCs (Figure 7). We detected localized
formation of actin filaments either in lamellipodia protrusions
(arrows in Figure 7A) or at other discrete domains (inlet in
Figure 7A) that were usually localized at one side of the nucleus.
Infection of MCP-1 stimulated cells with a retrovirus encoding
DN-FROUNT completely abrogated this process and resulted
in occurrence of stress fiber-like actin filaments (Figure 7B).
The formation of lamellipodia protrusions was efficiently
inhibited in these cells (Figure 7B). Similarly, pretreatment of
mBM-MASCs with the PI(3)K inhibitor Wortmannin before appli-
cation of MCP-1 diminished the formation of lamellipodia protru-
sions (Figure 7C). The combined treatment with DN-FROUNT
and Wortmannin did not result in a synergistic inhibition of lamel-
lipodia protrusions suggesting that FROUNT and PI(3)K did act
in the same pathway. Most likely, activated CCR2 results in
Figure 6. FROUNT Is Required for MCP-1-Induced Cluster Forma-
tion of CCR2 and Cell Polarization of mBM-MASCs
Immunofluorescence staining of mBM-MASCs for CCR2 (A, C, and E) and
FROUNT (B, D, and F) before (A and B) and after addition of MCP-1/CCL2
(C–F) in the absence (C and D) and presence (E and F) of DN-FROUNT. Addi-
tion of MCP-1 led to a relocalization of CCR2 and FROUNT and to cluster
formation usually at one side of the nucleus (C and D). Inhibition of FROUNT
by DN-FROUNT inhibited cluster formation and polarization of the cells (E
and F). mBM-MASCs were counterstained with DAPI to visualize all nuclei in
the culture.572 Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc.accumulation of PIP3 by PI(3)K in a FROUNT-dependent manner
to promote targeted migration of mBM-MASCs.
DISCUSSION
In this study, we have analyzed some of the cellular events that
lead to homing and tissue engraftment of intravenously injected
mBM-MASCs. Due to the therapeutic potential of mesenchymal
stem cells and related cell populations, several attempts have
been made recently to identify molecules that might promote
tissue-specific homing, although the receptors and cellular pro-
cesses that mediate such response have been largely neglected.
In a comprehensive survey of potential chemoattractants, Ozaki
and colleagues detected a strong chemotactic effect of PDGF-
BB on mesenchymal stem cells (MSCs) in vitro, although other
Figure 7. FROUNTMediates Localized Formation of Actin Filaments
and Generation of Lamellipodia
Immunofluorescence staining of mBM-MASCs to reveal formation of actin fil-
aments (red) after treatment with MCP-1 (A and B) after infection with a control
virus (A) and after expression of DN-FROUNT (B). (C) Relative number of mBM-
MASCs with lamellipodia; MCP-1-stimulated cells were set as 100% and com-
pared to the effects of different concentrations of Wortmannin (WM), a PI(3)K
inhibitor, of DN-FROUNT, and a combination of both. mBM-MASCs were
infected with DN-FROUNT or pretreated with Wortmannin for 1 hr before stim-
ulation with MCP-1. The occurrence of lamellipodia-positive cells was strongly
blocked by DN-FROUNT and by inhibition of PI(3)K. The combined inactivation
of FROUNT and PI(3)K had no further effect. Data represent mean ± SD (n = 4).
(D) 3D reconstruction of MCP-1 stimulated mBM-MASCs after staining for
filamentous actin (red), EGFP (green), and nuclei (blue).
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et al., 2007). In our assay system, the effects of PDGFs were
less pronounced, which might be explained by differences
between MSCs and mBM-MASCs. In a recent study, Schenk
et al. demonstrated enhanced homing of MSCs into infarcted
hearts that had been engineered by injection of cardiac fibro-
blasts expressing MCP-3 into the infarct border zone (Schenk
et al., 2007). Although the effects of MCP-3, which signals via
CCR1, CCR2, and CCR3, were significant, it seems difficult to
separate the effects of MCP-3 expression from the conse-
quences of tissue damage and hypoxia imposed by infarction.
We have resorted to a transgenic system designed to activate
the CCR2 receptor in vivo to prove that CCR2-mediated mobili-
zation and homing of mBM-MASCs is sufficient to direct cells
into a specific organ. Our focus was on events 7 and 14 days
after administration of mBM-MASCs, which makes sure that
we do not monitor transient interactions of incoming cells with
recipient organs but veritable homing and engraftment pro-
cesses. The transgenic expression of MCP-1 in the heart seems
to guarantee that we primarily analyze effects of this cytokine
and not effects that are imposed by external damages. Never-
theless, one has to consider that extended expression
of MCP-1 in the heart does also trigger secondary processes
(Kolattukudy et al., 1998), although we have used MCP-1 trans-
genic animals at an age in which they had not yet encountered
major pathological changes in the heart (Martire et al., 2003).
Clearly, distinct conditions within the myocardium are required
to attract significant numbers of transplanted mBM-MASCs. In-
terestingly, we did not find a preferential accumulation of mBM-
MASCs in hearts of desmin knockout mice suffering from severe
cardiomyopathy (Milner et al., 1999) (data not shown), while
a strong engraftment of mBM-MASCs was detected in the BZ
of hearts damaged by ischemia/reperfusion, which reached (at
least locally in the BZ) similar levels as in hearts of MCP-1 trans-
genic animals. Intriguingly, both models (ischemia/reperfusion
and MCP-1 overexpression) are characterized by a high degree
of mononuclear cell infiltration and inflammatory reactions,
which might explain why mBM-MASCs were efficiently attracted
by a cytokine that has been thought to be primarily involved in
the attraction of macrophages. The ischemia/reperfusion model
does also demonstrate the physiological relevance of MCP-1
FROUNT-mediated clustering of CCR2 for the control of homing
of mBM-MASCs into diseased organs.
Our study does not address the question whether and how
mBM-MASCs might improve local repair processes, yet some
implications for the therapeutic application of stem cells are
apparent. Clearly, stimulation of the CCR2/FROUNT/PI(3)K sig-
nal transduction pathway might help to summon different popu-
lations of mesenchymal stem cells to the heart or to other tissues
in order to contribute to tissue remodeling and to aid recruitment
of additional cells. As a caveat, one has to be aware that the
CCR2/FROUNT/PI(3)K cascade is not unique to stem cells.
Monocytes chemoattractant proteins (MCPs) and their receptors
play pivotal roles in the development of inflammatory responses
and are crucial for the transmigration of immune cells to sites of
inflammation. CCR2 is a major receptor for MCP-1 (CCL2) and
other MCPs, including CCL8 (MCP-2) and CCL7 (MCP-3) (Charo
and Peters, 2003). Because CCR2 regulates monocytes and
macrophage recruitment and is necessary for macrophage-de-pendent inflammatory responses, it has been proposed that in-
hibition of FROUNT might be used to fight various chronic inflam-
matory immune diseases by preventing infiltration of tissues by
macrophages (Terashima et al., 2005). Our results suggest that
such an approach will most certainly also block homing of mes-
enchymal stem cells, which seem to modulate inflammatory
response and improve repair processes (Schenk et al., 2007).
Along the same line: a simple enhancement of tissue engraft-
ment of mesenchymal stem cell by overexpression or injection
of single chemoattractants will most likely lead to engraftment
of multiple cell types, including inflammatory cells, which might
cause an enhanced inflammatory reaction thereby interfering
with tissue repair.
It seems unlikely that homing of circulating cells depends on
a single molecule or pathway. Therefore, it was interesting to
note that expression of dominant-negative FROUNT did abro-
gate homing of mBM-MASCs into myocardium damaged by
ischemia/reperfusion, thereby indicating that FROUNT-medi-
ated migratory processes are pivotal for the recruitment of
mBM-MASCs into the ischemically damaged heart. Apparently,
FROUNT-mediated signaling is a limiting step in the homing pro-
cess that cannot be easily replaced or bypassed by other signal-
ing events independent of the complex nature of regulatory
mechanisms that ascertain recruitment of circulatory cells.
We have also shown that engrafted mBM-MASC express
SDF-1 and also stimulate accumulation of SDF-1-positive cells
in their vicinity. The expression of SDF-1 by mBM-MASCs that
have engrafted into a recipient tissue might therefore initiate an
additional regulatory circuit that leads to the entrapment of circu-
lating cells. Based on our findings, we propose the following
model for CCR2/FRONT-mediated homing of mBM-MASCs
(Figure S10). Before stimulation of mBM-MASCs, CCR2 and
FROUNT are evenly distributed within the cytoplasm or at a peri-
nuclear localization. Binding of MCP-1 to CCR2 activates the
receptor and recruits FROUNT, resulting in the formation of
clusters of CCR2 and FROUNT at the plasma membrane. The
formation of clusters of CCR2 and FROUNT goes along with
the polarization of cells as indicated by the asymmetric distribu-
tion of CCR2/FROUNT clusters at either side of the nucleus. The
association of FROUNT with CCR2 leads to activation of PI(3)K,
which results in localized formation of actin filaments and lamel-
lipodia protrusions. In principle, our model is compatible with the
idea of ‘‘local excitation, global inhibition,’’ which explains why
cells respond to changes in receptor occupancy and adapt
when occupancy is held constant (Devreotes and Janetopoulos,
2003). The strong polarization of mBM-MASCs, which occurred
even when the chemoattractant was not supplied as a gradient,
might only be explained by a strong ‘‘positive feedback loop’’
that selectively amplifies a signal at specific sites of the cell
and, therefore, localizes the response (Meinhardt, 1999). The
recruitment of FROUNT to the activated CCR2 receptor seems
to be an important component of this loop since DN-FROUNT
prevented localized responses and cell polarization. At present,
it remains unclear whether the profound changes in proliferation
characteristics and cellular morphology of mBM-MASCs after
FROUNT overexpression were caused by activation of the
FROUNT/PI(3)K-Rac pathway or whether additional signaling
cascades were initiated. Further research will be necessary to
solve this question.Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc. 573
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RNA Isolation, RT-PCR, Quantitative Real-Time RT-PCR,
and Western Blot Analysis
RNA isolation, reverse transcription-PCR (RT-PCR), and quantitative real-time
PCR analyses were performed as described previously (Ebelt et al., 2007).
Detailed protocols and primer sequences are available on request. The homing
index of mBM-MASCs-eGFP and mBM-MASCs-DNF was displayed as the ra-
tio of the normalized expression of EGFP to a reference transcript (GAPDH).
Relative expression levels under different experimental conditions were com-
pared based on the expression level of the gene of interest. Western blot anal-
ysis was performed as described (Ebelt et al., 2007).
Microarray Analysis
RNA was isolated from undifferentiated mBM-MASCs1 and -2 and hybridized
onto GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Each cell line was
represented by three biological replicates. GeneChip hybridization and bioti-
nylated cRNA detection were done according to standard Affymetrix proto-
cols. The raw data were processed by the robust multiarray average (RMA)
method (Irizarry et al., 2003).
Construction of Recombinant Lentiviruses and Infection
of mBM-MASCs
Full-length FROUNT and dominant-negative (DN)-FROUNT cDNAs (Tera-
shima et al., 2005) were cloned into the c-FUW lentivirus transfer vector
(Lois et al., 2002). All constructs were verified by sequence analysis. mBM-
MASCs were subjected to FACS to separate infected from noninfected cells
using the EPICS ELITE ESP cell sorter (Beckman Coulter).
Immunofluorescence Staining
eGFP-labeled mBM-MASCs were visualized using a polyclonal rabbit anti-
eGFP primary antibody and Alexa594 anti-rabbit secondary antibody (Molec-
ular Probe). Goat polyclonal antibodies directed against FROUNT also known
as Nup85 (mouse) and Nup75 (human) were purchased from Santa Cruz. A
rabbit monoclonal antibody to CCR2 was obtained from Abcam. The second-
ary detection system was biotinylated anti-mouse or anti-rabbit IgG (Biotrend)
conjugated with Cy-2, Cy-3, or Cy-5. Nuclei were stained with TOTO-3, Draq5
(Molecular Probes), and Hoechst 33258 (Dako). The samples were examined
with confocal scanning laser microscopes Leica TCSNT and Leica TCS
SP2SE as described (Kostin et al., 2003).
Engrafted cells in different organs were counted per microscopic field (mag-
nification 2003) from 400 microscopic fields randomly selected from 40 sec-
tions (10 fields/section) from each organ and animal (n = 6 for MyHC-MCP-1
mice). Mice damaged by ischemia/reperfusion were analyzed using the
same approach, but in this case, 150 randomly chosen microscopic fields
from 15 sections (10 fields/section) were counted (n = 5). Mean values and
SD were calculated using the total number of cells from each organ and
animal.
In Vitro Migration Assay
Migration assays were performed in a chemotaxis chamber as described
previously (Neuhaus et al., 2003). Migration assays were performed by adding
serum-free DMEM supplemented with individual chemoattractants (concen-
tration range between 0.1 and 1000 ng/ml) into the lower chemotaxis chamber.
The upper chemotaxis chamber was loaded with 25,000 cells in DMEM low
glucose. Cells that which had migrated toward the lower chamber were visu-
alized by Hoechst 33258 (Dako) staining. The migration index was calculated
based on the ratio of cells that migrated in response to chemoattractants to
cells that migrated randomly in absence of chemoattractants. The ratio result-
ing from random migration was set to zero. The area occupied by labeled
nuclei was quantified using the ImageJ software.
Cell Culture and Tail Vein Injection of Mice
mBM-MASCs from male ICR mice were derived as described previously
(Belema-Bedada and Braun, 2008; Belema-Bedada et al., 2005). This isolation
procedure is mainly based on two enrichment steps: (1) differential adherence
of cells to the surface of tissue culture dishes and (2) slow growth under
adverse culture conditions with low growth factor concentrations (‘‘attrition’’).574 Cell Stem Cell 2, 566–575, June 2008 ª2008 Elsevier Inc.For experiments, freshly isolated individual clones were used at low passage
numbers (<25) after phenotyping by FACS analysis. Descendants of trans-
planted, EGFP-labeled mBM-MASCs were isolated from the bone marrow us-
ing the same procedure, but employing EGFP-based FACS as the last purifi-
cation step. EGFP expression was directed by integrated EGFP-encoding
lentiviruses. Cells were karyotyped by ‘‘color karyotyping’’ (mFISH) as
described (Liyanage et al., 1996).
The long-term renewing capacity of mBM-MASCs was assessed by serial
transplantation of mBM-MASCs into the tail vein and (re)isolation from the
bone marrow. The generation of MyHC-MCP-1 mice has been described
previously (Kolattukudy et al., 1998). For tail vein injection, 2.5 to 33 105 cells
suspended in 75 ml PBS were injected into tail veins of 12- to 16-week-old
MyHC-MCP-1 and control mice (Martire et al., 2003). Adult female ICR mice
underwent ischemia/ reperfusion following the same procedure as described
before for permanent LAD ligations (Ebelt et al., 2007), but with opening the
ligature after 90 min.
SUPPLEMENTAL DATA
The Supplemental Data include ten figures and can be found with this article
online at http://www.cellstemcell.com/cgi/content/full/2/6/566/DC1/.
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